Share Price | Coeptis Therapeutics Holdings, Inc. Stock Analysis & Recommendation

Q: Is Coeptis Therapeutics Holdings, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Coeptis Therapeutics Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the monthly RSI indicates a bearish stance. Bollinger Bands show a mildly bullish trend for both weekly and monthly periods. The KST is bullish across both time frames, but the OBV is mildly bearish on a weekly basis. Overall, the indicators suggest a mildly bullish stance with some conflicting signals.In terms of performance, the stock has had a remarkable year-to-date return of 128.18%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the past month with a return of -14.36% compared to the S&P 500's 2.33%.

Q: How big is Coeptis Therapeutics Holdings, Inc.?

Market Cap: As of Jun 18, Coeptis Therapeutics Holdings, Inc. has a market capitalization of 28.85 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Coeptis Therapeutics reported net sales of 0.06 million and a net profit of -11.30 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 5.29 million, while total assets were reported at 11.01 million.

Q: What does Coeptis Therapeutics Holdings, Inc. do?

Overview: Coeptis Therapeutics Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025). Market cap: USD 28.85 Million (Micro Cap).Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.33. Return on Equity: -167.63%. Price to Book: 4.29.Contact Details: No Company Details Available. Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

602.79 k

Shareholding (Mar 2026)

FII

0.46%

Held by 5 FIIs

DII

99.55%

Held by 6 DIIs

Promoter

0.00%

Is Coeptis Therapeutics Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Coeptis Therapeutics Holdings, Inc. shows a mildly bullish trend with conflicting technical indicators, having a year-to-date return of 128.18% but underperforming in the last month with a -14.36% return compared to the S&P 500's 2.33%.

View full answer

How big is Coeptis Therapeutics Holdings, Inc.?

22-Jun-2025

As of Jun 18, Coeptis Therapeutics Holdings, Inc. has a market capitalization of 28.85 million, with net sales of 0.06 million and a net profit of -11.30 million over the last four quarters. The company's shareholder's funds are 5.29 million, and total assets are 11.01 million as of Dec 24.

View full answer

What does Coeptis Therapeutics Holdings, Inc. do?

22-Jun-2025

Coeptis Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $3 million as of March 2025, with a market cap of $28.85 million. Key financial metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -167.63%.

View full answer

Compare Coeptis Therapeutics Holdings, Inc. with Similar Stocks

Enlivex Therapeutics Ltd.Unity Biotechnology, Inc.Alaunos Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Positive results in Mar 26

Risky -

Increasing Participation by Institutional Investors

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 66 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.35

Return on Equity

-77.96%

Price to Book

3.85

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Mar 2026)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

50.59%

6 Months

14.28%

1 Year

116.71%

2 Years

157.7%

3 Years

-53.27%

4 Years

-91.71%

5 Years

-91.55%

Coeptis Therapeutics Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

18.74%

EBIT Growth (5y)

-264.29%

EBIT to Interest (avg)

-4.98

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.33

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

17.36%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.85

EV to EBIT

-4.63

EV to EBITDA

-5.11

EV to Capital Employed

5.41

EV to Sales

44.30

PEG Ratio

Dividend Yield

ROCE (Latest)

-116.81%

ROE (Latest)

-77.96%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (6.01%)

Foreign Institutions

Held by 5 Foreign Institutions (0.46%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -17.65% vs -13.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.60",
          "val2": "-3.80",
          "chgp": "5.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.20",
          "val2": "0.60",
          "chgp": "-133.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.00",
          "val2": "-3.40",
          "chgp": "-17.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-34,408.10%",
          "val2": "-64,525.60%",
          "chgp": "3,011.75%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -12.84% vs 48.83% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.80",
          "val2": "-9.00",
          "chgp": "-31.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.50",
          "chgp": "20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "-0.60",
          "chgp": "300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.30",
          "val2": "-10.90",
          "chgp": "-12.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,569.40%",
          "val2": "0.00%",
          "chgp": "-956.94%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.10

Operating Profit (PBDIT) excl Other Income

-3.60

-3.80

5.26%

Interest

0.00

0.10

-100.00%

Exceptional Items

-0.20

0.60

-133.33%

Consolidate Net Profit

-4.00

-3.40

-17.65%

Operating Profit Margin (Excl OI)

-34,408.10%

-64,525.60%

3,011.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -17.65% vs -13.33% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1.40

0.00

Operating Profit (PBDIT) excl Other Income

-11.80

-9.00

-31.11%

Interest

0.60

0.50

20.00%

Exceptional Items

1.20

-0.60

300.00%

Consolidate Net Profit

-12.30

-10.90

-12.84%

Operating Profit Margin (Excl OI)

-9,569.40%

0.00%

-956.94%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -12.84% vs 48.83% in Dec 2024

All Annual Results

Company CV

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available